Celltrion Partners with iProgen Biotech to develop a series of novel ADCs

Celltrion signs a partnership deal with the Canada-based iProgen Biotech Inc. to bolster its pipeline for novel biotherapeutics. The deal aims to co-develop up to 4 ADCs including a novel ADC (Antibody-drug conjugate) that targets breast cancers expressing low levels of HER2 using iProgen’s proprietary antibody drug delivery technology